Change in the Scale for the Assessment of Negative Symptoms 8 week double-blind study period; baseline and 8 weeks [clinicaltrials_resource:baa52dca8e3011738d48795a536f4a7e]
Measures change in affective flattening or blunting, alogia, avolition/apathy, anhedonia/asociality, attention; minimum score = 0; maximum score = 125; lower values are considered a better outcome
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Change in the Scale for the Assessment of Negative Symptoms 8 week double-blind study period; baseline and 8 weeks [clinicaltrials_resource:baa52dca8e3011738d48795a536f4a7e]
Measures change in affective flattening or blunting, alogia, avolition/apathy, anhedonia/asociality, attention; minimum score = 0; maximum score = 125; lower values are considered a better outcome
Bio2RDF identifier
baa52dca8e3011738d48795a536f4a7e
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:baa52dca8e3011738d48795a536f4a7e
measure [clinicaltrials_vocabulary:measure]
Change in the Scale for the Assessment of Negative Symptoms
time frame [clinicaltrials_vocabulary:time-frame]
8 week double-blind study period; baseline and 8 weeks
description
Measures change in affective f ...... re considered a better outcome
identifier
clinicaltrials_resource:baa52dca8e3011738d48795a536f4a7e
title
Change in the Scale for the As ...... y period; baseline and 8 weeks
@en
type
label
Change in the Scale for the As ...... 52dca8e3011738d48795a536f4a7e]
@en